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rug-Eluting Stents
ore Dollars Than Sense?*
unil Garg, MD,†‡ Mark J. Eisenberg, MD, MPH‡§
ontreal, Quebec, Canada
he clinical and economic analysis by Eisenstein et al. (1) in
his issue of JACC: Cardiovascular Interventions is a welcome
ddition to the collective literature on the cost-effectiveness of
rug-eluting stents (DES). There are limited trial data regard-
ng this topic, and most appraisals have been based on registry
ssessments. Eisenstein et al. (1) present the long-term clinical
nd economic analysis of a trial comparing a DES (zotaroli-
us, Endeavor, Medtronic CardioVascular, Santa Rosa, Cal-
fornia) versus a bare-metal stent (BMS) (Driver, Medtronic
ardioVascular). The inclusion of data up to 4 years post-
ndex procedure is particularly important given concerns with
ate stent thrombosis with DES.
See page 1178
The ENDEAVOR II trial was an international, random-
zed, double-blind study that assessed the safety and efficacy of
he Endeavor DES (2). A total of 1,197 patients with a single,
e novo lesion in a native coronary artery were randomized to
eceive either the Endeavor (n  598) or Driver (n  599)
tent. The patients had either clinical evidence of ischemia or
positive functional study and could not have had a myocardial
nfarction in the preceding 72 h. The investigators performed
n economic assessment of the patients in the ENDEAVOR
I trial with Medicare cost weights and quality-of-life adjust-
ents applied from secondary sources. They compared the
ifferences through a 4-year follow-up period. They found that
he Endeavor stent significantly reduced the rate of 4-year
arget vessel revascularization (TVR) versus the Driver stent.
here was no difference in the rates of death or nonfatal
yocardial infarction. These findings are consistent with
revious DES safety studies for Cypher (Cordis, Johnson &
ohnson, Bridgewater, New Jersey) and Taxus (Boston Scien-
ific, Natick, Massachusetts) stents (3,4).
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the *Division of Cardiology, McGill University Health Centre, and the
Department of Epidemiology, Biostatistics, and Occupational Health and thew
Divisions of Cardiology and Clinical Epidemiology Jewish General Hospital,
cGill University, Montreal, Quebec, Canada.The primary clinical and economic benefit of a DES is the
eduction in follow-up TVR and its associated costs. A
isease-specific cost-effectiveness analysis was performed to
ssess the incremental costs per TVR avoided. There was an
1.1% reduction in TVR. Although the index procedure was
ore expensive in the DES group, the lower rates of follow-up
VR resulted in DES becoming cost neutral. The 4-year cost of
DES approach was $21,873 versus $22,167 for the BMS group.
Prior to the present study, there were 2 other trials that
rospectively examined the cost effectiveness of DES com-
ared with BMS in the U.S. The first was conducted as a
ubstudy of the SIRIUS (Sirolimus-Eluting Balloon ex-
andable Stent in the treatment of Patients with De Novo
ative Coronary Artery Lesions) trial (3), which compared
irolimus-eluting stents with BMS. The second trial was a
ubstudy of the TAXUS IV trial, which compared
aclitaxel-eluting stents with BMS (4).
In the SIRIUS trial, patients randomized to DES had costs
f index hospitalization that were higher than patients ran-
omized to BMS. However, patients randomized to BMS had
otal follow-up costs that were higher than patients random-
zed to DES. This led to similar cumulative 1-year follow-up
osts between the 2 groups. The TAXUS IV trial substudy had
imilar results. Both trials followed patients for only 1 year. A
ecently published cost-effectiveness assessment (5) extrapo-
ated data from these trials and included the cost of clopidogrel
ver an additional 2-year period. After including the extra cost
f clopidogrel to prevent late stent thrombosis, the analysis
emonstrated a substantially increased cost for DES. The
uthors concluded that an across-the-board use of DES is not
ost-effective in the U.S. in terms of cost per quality-adjusted
ife year (QALY) gained and cost per TVR avoided.
Eisenstein et al. (1) examined their data and noted that there
ere no major differences in the utilization of dual antiplatelet
herapy between the 2 groups over the 4 years of the study. On
he other hand, they were unable to take into account the
ajor shift that has occurred in the management of patients
ith DES since their data were collected. The trial data were
ollected between July 2003 and January 2004, and both
roups were assigned to 12 weeks of dual antiplatelet therapy.
n 2004, the risk of late stent thrombosis had not yet been
ecognized, and it was considered safe to discontinue dual
ntiplatelet therapy in patients with Cypher stents at 12
eeks and with Taxus stents at 24 weeks. However, follow-
ng the discovery of risk of late stent thrombosis for DES,
atients are now maintained on dual antiplatelet therapy for
longer period of time.
The investigators demonstrated a statistically insignificant
ifference between the 2 groups with regards to the use of dual
ntiplatelet therapy over the 4-year period. However, this does
ot reflect the current clinical practice of maintaining patients
ith DES on clopidogrel for a minimum of 1 year, and in
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1189ome cases indefinitely. Prior studies have estimated the costs
f such dual antiplatelet therapy to be roughly $2,500 over 2
ears (5). If factored over the 4 years of the ENDEAVOR II
tudy, this extra expenditure would increase the cost associated
ith DES to the point that it would no longer be cost effective.
urthermore, the patients who received BMS could have
topped their dual antiplatelet therapy as early as 4 weeks if no
oncomitant acute coronary syndrome were present, thus
agnifying further the cost differential between the 2 arms.
There are extensive data proving DES effectively reduce the
ate of in-stent stenosis and that they are an important tool in
he arsenal of interventional cardiologists. Convincing data
emain absent, however, that DES are cost saving or that they
re cost neutral. A considerable amount of money must be
pent for a modest long-term clinical benefit since DES have
o impact on mortality or myocardial infarction rates and
ecause their effect on quality of life appears modest (6). Given
he ever-increasing scrutiny on health care expenditures and
he increasingly important need for fiscal responsibility, an
ll-embracing use of DES cannot be advocated at this time.
ES are likely only to be cost effective in highly selected
roups of patients at particularly high risk for restenosis. Given
he risk of late stent thrombosis and the need for long-term
ual antiplatelet therapy, future studies should include the cost
f extended thienopyridine use in order to determine the true
ost of DES. In our opinion, a nonselective use of DES
urrently involves more dollars than sense. veprint requests and correspondence: Dr. Mark J. Eisenberg,
ivisions of Cardiology and Clinical Epidemiology, Sir Mortimer
. Davis Jewish General Hospital/McGill University, 3755 Cote
te. Catherine Road, Suite A-118, Montreal, Quebec H3T 1E2,
anada. E-mail: mark.eisenberg@mcgill.ca.
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